Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We are evaluating those variations as well as some of the things that -- we've got just a really, really strong -- over the last year, we've brought on some of the best R&D guys going when it comes to the biologics world |
| Our business is performing exceptionally well, and we are excited about our growth potential, which continues to rise with our continued execution |
| The sustained robust demand for our OsteoFactor and OsteoVive Plus products since their initial launch has been a driving force in our success with the $2.4 billion U.S |
| These critical initiatives have the company poised to achieve sustainable long-term growth and take additional share of the large and growing U.S |
| Notably, we delivered record quarterly revenue of $25 million, an increase of 73% year-over-year |
| The strong growth was driven by our core Xtant business, which includes organic growth of 18% and further bolstered by contributions from our recent acquisitions |
| I want to reemphasize our strong organic growth in the quarter when we were in the process of digesting 2 very complicated acquisitions |
| Overall, we are very proud of the tremendous strides that we have made as an organization in recent years |
| Our revenue growth and efficiently run operations are driving our bottom line as we recorded our second consecutive quarter of adjusted EBITDA |
| Altogether, our business is clicking on all cylinders, giving us more confidence regarding our future prospects |
| So I think that there's more and more opportunities that are going to be coming our way, especially for those companies that are in a strong financial position, like we are and companies that can show to potential companies not only how they can win in way of getting an exit, but then having hopefully a substantial win as they hopefully take more of our stock as it goes up as well |
| Xtant is strategically moving forward, and we have solid products, operations and talent to back it up |
| It has been a great fit that is helping us rapidly expand our commercial footprint with new contracts and distributors |
| We believe there is significant room for continued upside as we remain focused on streamlining operations and capitalizing on synergistic opportunities |
| Our record quarterly revenue demonstrates that we are successfully executing on each of our 4 strategic growth pillars |
| These actions have successfully boosted both production and overall efficiency |
| And by raising our revenue guidance and delivering positive adjusted EBITDA for 2 consecutive quarters, these accomplishments further demonstrate the progress that we are making |
| I've been very, very pleased with what our funnels look like, what are -- just the commercial integration that's taking place, so -- which is quite frankly, that's the bigger one, right? That's the big one |
| One of them -- I mean, again, I'd like to say that this was part of our great due diligence that we saw this terrific DCI product, which is a dynamic cervical implant, and it's a fantastic product |
| And so with that, I'm really excited that when you look at the new surgeon sign-ons that we're getting are higher or up -- certainly up even from a year ago when Surgalign had the business, our funnels look really, really strong |
| So by us owning the facility, essentially buying 2 years of inventory, all of that -- all of those economics are in our hands, right? So we think that we have -- it's a very good product |
| So a, we think we've got a great product |
| And so for us, we saw great value because we saw product lines like Coflex product lines like just the hardware and the biologics businesses |
| This robust 73% annual increase contributed primarily to greater independent agent sales, contributions from the Coflex and Cofix product lines, opportunistic private label sales and product sales from the recently acquired Surgalign Hardware and Biologics business |
| And so we're really very excited about that and what they're bringing to us |
| Notably, our expanded capacity has translated into increased OEM sales |
| So that's something that's in Europe today, doing very well |
| So yes, we have a very robust M&A pipeline |
| The updated guidance now includes contributions from the Surgalign acquisitions in addition to the strength of our organic business |
| [Indiscernible] Surgalign and now NanOss deals have met our acquisition criteria, marking significant milestones that are key for us in achieving our long-term goals |
| Statement |
|---|
| We anticipate that this current stem cell shortage will adversely impact fourth quarter revenues |
| I think about each of these businesses, all of them were businesses that were in tough shape, quite frankly, from neglect |
| And so by buying the product from RTI and a product line that had been going down again, it's just a little bit of -- it's a bit of a challenge within that market because it does require high commission |
| However, since this recall, donor availability has been limited and has adversely affected our stem cell business |
| So as I said, these are all 3 businesses that have had -- were neglected |
| And to answer the first part of that -- or the last part of that question first, yes, that's the hope here, right? But one of the challenges that NanOss has had is the economics for the business hasn't been great |
| And so when that got slowed down, some of that momentum for them stopped |
| Adjusted EBITDA for the third quarter of 2023 was $0.5 million compared to an adjusted EBITDA loss of $0.9 million for the same period in 2022 |
| And then in 2 months, we lost 3 more guys |
| And quite frankly, I think both valuations are finally starting to come down, but then the other part of it is the fact that I do think that a lot of these companies that are capital constrained are starting to waiver under some of these debt obligations |
| Net income in the third quarter of 2023 was $9.2 million or $0.07 per share compared to a net loss of $2.4 million or $0.03 per share in the comparable 2022 period |
| But this is a business though that still is taking a little more time for us to get the kind of traction we expected |
| And so if you don't have high margins in there, it's hard to be able to compete |
Please consider a small donation if you think this website provides you with relevant information